Category: freely available

Drug researcher up to ten retractions

A pharmaceutical researcher has received his tenth retraction. The reason, once again: duplicating his previous work.

Giuseppe Derosa, based at the University of Pavia in Italy, lost a 2011 paper this month after journal editors identified “substantial duplication of an earlier published paper.” According to the notice, the authors failed to cite the previous work and to disclose that the manuscript had been published or was under consideration elsewhere.

Derosa has a habit of reusing clinical trial data in multiple papers. He received his first four retractions in 2015 for publishing the same clinical trial results six times—two of those papers were retracted over the summer and two more several months later. By 2016, a fifth from the bunch was retracted (one of the six still stands). Derosa received another retraction, citing duplication (which we covered here and which was not related to the six clinical trials).

Continue reading Drug researcher up to ten retractions

BMJ journal yanks paper on cancer screening in India for fear of legal action

BMJ Global Health has pulled a paper that criticized U.S. research of the effects of cervical cancer screening in India over defamation concerns.

That’s not what the notice on the paper says, however — at the moment, it just reads:

This article has been withdrawn.

However, forwarded email correspondence between the first author and an associate publisher reveals the journal published the paper and planned a press release, then realized it should be reviewed by a legal adviser. When first author Eric J. Suba at Kaiser Permanente San Francisco Medical Center inquired about the status of the paper and any potential press release, he was told the journal could no longer publish it, out of concern they would be taken to court.

Suba told us that, when he learned the paper would be pulled:

Continue reading BMJ journal yanks paper on cancer screening in India for fear of legal action

“There is an injustice in this article”

The editors of a plant biology journal have retracted a 2007 paper because of “an injustice.”

According to the notice, the editors of Cytologia found evidence of “apparent figure manipulation,” and decided to retract the paper.

This marks the 10th retraction for plant biologist Dibyendu Talukdar.

Talukdar, who is first and corresponding author on the 2007 paper and listed at the University of Calcutta in West Bengal, India, received his first retraction last July, which also cited suspected figure manipulation. Earlier this year, Talukdar received eight more retractions in seven different journals, all describing concerns over potential image duplication and manipulation.

Here’s the most recent retraction notice in Cytologia: Continue reading “There is an injustice in this article”

Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

A neurochemistry journal has retracted a paper from a group in China over a duplicated image.

According to the notice, the authors used the same image in the two papers to represent different experimental conditions. The only distinguishing feature between the images: “apparent brightness changes.”

The authors defended their actions, explaining that the research published in Journal of Neurochemistry “sequentially builds” on their previous study in Journal of Neuroinflammation, which they mention in the 2015 paper’s discussion. In the notice, the authors were quoted saying:  Continue reading Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

On April 27, the Journal of Biological Chemistry (JBC) retracted nine papers by a researcher based in Israel, including some dating back to 2000.

The reason: Image manipulation.

Michal Neeman, vice president of The Weizmann Institute of Science, told us that the researcher, Rony Seger, is under investigation following an allegation of misconduct affecting papers in multiple journals.

So far, we’ve found 11 retractions for papers by Seger, a molecular biologist. In the notices, the authors state they have “full confidence” in the findings, and in many instances have replicated the work.

According to Neeman:

Continue reading Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

Authors retract much-debated blockchain paper from F1000

The authors of a popular — and heavily debated — F1000Research paper proposing a method to prevent scientific misconduct have decided to retract it.

The paper was initially criticized for allegedly plagiarizing from a graduate student’s blog — and revised to try to “rectify the overlap.” But according to F1000, it is now being retracted after an additional expert identified problems with the methodology.

Today, F1000 added this editorial note to the paper:

Continue reading Authors retract much-debated blockchain paper from F1000

Author retracts nanotechnology paper over doubts about key results

The corresponding author of a 2015 nanotechnology paper has penned a lengthy — and revealing — retraction notice, explaining why he is not certain about the findings.

In the notice, Chang Ming Li from the Institute for Clean Energy & Advanced Materials (ICEAM) at Southwest University in China, states that there is “insufficient evidence to conclusively” identify the composition of the nanowire array described in the article, which “severely undermines the validity of the reported conclusions.”

The 2015 paper has been considered “highly cited” by Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters, meaning it has received a disproportionate amount of cites given its field and publication year.

Li also said that the paper — which appeared in Physical Chemistry, Chemical Physics — was “submitted and published without my knowledge or permission.” He has not responded to our request to explain how that could have happened, given that he was the corresponding author. Continue reading Author retracts nanotechnology paper over doubts about key results

Reuters removes story on gender confirmation surgery because firm mistakenly released data

Reuters has removed a story about gender confirmation surgery, saying it included problematic data.

The public relations firm representing the American Society of Plastic Surgeons (ASPS) — which generated the data in the report  — took responsibility, saying it supplied Reuters with data the ASPS did not want released.

Yesterday, Reuters pulled its version of a widely-reported story about an increase in such surgeries in the U.S. (Later, it pulled the withdrawal notice as well, only to make it reappear at a different URL.)

The story, originally posted just after midnight yesterday, reported a 19 percent increase in those procedures from 2015 to 2016, based on data provided the American Society of Plastic Surgeons (ASPS). Around 1 pm US Eastern time that day, Reuters put up a withdrawal notice in place of the original story:

Continue reading Reuters removes story on gender confirmation surgery because firm mistakenly released data

Researchers mistakenly administer three-fold higher dose of anesthesia

Researchers have retracted a 2016 paper after discovering that they accidentally administered three times the reported dose of anesthesia to rats.

In the Experimental Physiology paper, the authors set out to mathematically map how rats’ blood pressure changes under different conditions, which required the rats to be anesthetized. But their findings were called into question when they found the rats had received a much higher concentration of anesthesia than intended. According to the notice, this higher dose compromised the “objectives of the experiment.”

The corresponding author Karol Ondrias, from the Institute of Molecular Physiology and Genetics at the Slovak Academy of Sciences in Bratislava, told us how the dosing error occurred: Continue reading Researchers mistakenly administer three-fold higher dose of anesthesia

Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12)

A diabetes journal has issued two notices of concern for papers co-authored by a researcher who took another publisher to court after it did the same thing — but ultimately lost.

The notices are for two papers co-authored by Mario Saad — who, after losing his legal battle with the American Diabetes Association, has since accumulated 12 retractions. Both notices — from the journal Diabetologia, published by Springer and the the European Association for the Study of Diabetes (EASD) — say they have alerted Saad to their concerns about some of the images in the papers, and the university where he is based was asked to investigate more than one year ago. Since the journal has not yet received any information from the University of Campinas in Brazil, however, it decided to issue expressions of concern for the two papers.

Here’s the text of the first notice:

Continue reading Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12)